ADMA Biologics, Inc. (ADMA)
After hours:
| Previous Close | 2.0200 |
| Open | 1.9900 |
| Bid | 1.9500 x 2900 |
| Ask | 2.0700 x 900 |
| Day's Range | 1.9301 - 2.1000 |
| 52 Week Range | 1.0100 - 2.1550 |
| Volume | |
| Avg. Volume | 2,665,695 |
| Market Cap | 393.586M |
| Beta (5Y Monthly) | 1.16 |
| PE Ratio (TTM) | N/A |
| EPS (TTM) | -0.6280 |
| Earnings Date | Mar 23, 2022 - Mar 28, 2022 |
| Forward Dividend & Yield | N/A (N/A) |
| Ex-Dividend Date | N/A |
| 1y Target Est | 5.13 |
- Zacks
Adma Biologics (ADMA) Reports Q1 Loss, Tops Revenue Estimates
Adma Biologics (ADMA) delivered earnings and revenue surprises of -25% and 9.82%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
- GlobeNewswire
ADMA Biologics Announces First Quarter 2022 Financial Results and Provides Business Update
First Quarter 2022 Total Revenues Were Approximately $29.1 Million, an 81% Increase Over First Quarter 2021 Increases Full Year 2022 Total Revenue Guidance to $130 Million or More From $125 Million Gross Margin Growth and Narrowing Net Losses Expected Throughout 2022 and Beyond RAMSEY, N.J. and BOCA RATON, Fla., May 11, 2022 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing a
- Simply Wall St.
What Kind Of Shareholders Own ADMA Biologics, Inc. (NASDAQ:ADMA)?
A look at the shareholders of ADMA Biologics, Inc. ( NASDAQ:ADMA ) can tell us which group is most powerful. Large...
